Biotron Ltd (BIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biotron Ltd (BIT) has a cash flow conversion efficiency ratio of -0.322x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-868.42K ≈ $-614.46K USD) by net assets (AU$2.70 Million ≈ $1.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Biotron Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Biotron Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Biotron Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Biotron Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotron Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
-0.123x |
|
BPH Energy Ltd
AU:BPH
|
-0.008x |
|
Akshar Spintex Limited
NSE:AKSHAR
|
0.025x |
|
St-Georges Eco-Mining Corp
F:85G1
|
0.001x |
|
Knosys Ltd
AU:KNO
|
-0.200x |
|
Shamaym Improve Ltd
TA:SHMM
|
1.183x |
|
BlackRock Frontiers Investment Trust plc
LSE:BRFI
|
-0.044x |
|
Chijet Motor Company, Inc. Ordinary Shares
NASDAQ:CJET
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Biotron Ltd (2001–2025)
The table below shows the annual cash flow conversion efficiency of Biotron Ltd from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see BIT company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$551.89K ≈ $390.50K |
AU$-565.80K ≈ $-400.34K |
-1.025x | -107.01% |
| 2024-06-30 | AU$-244.03K ≈ $-172.67K |
AU$-3.57 Million ≈ $-2.52 Million |
14.623x | +1510.16% |
| 2023-06-30 | AU$3.17 Million ≈ $2.24 Million |
AU$-3.29 Million ≈ $-2.33 Million |
-1.037x | +53.49% |
| 2022-06-30 | AU$1.09 Million ≈ $773.01K |
AU$-2.44 Million ≈ $-1.72 Million |
-2.230x | -152.78% |
| 2021-06-30 | AU$3.86 Million ≈ $2.73 Million |
AU$-3.41 Million ≈ $-2.41 Million |
-0.882x | -99.59% |
| 2020-06-30 | AU$6.97 Million ≈ $4.93 Million |
AU$-3.08 Million ≈ $-2.18 Million |
-0.442x | -60.48% |
| 2019-06-30 | AU$5.44 Million ≈ $3.85 Million |
AU$-1.50 Million ≈ $-1.06 Million |
-0.275x | +80.84% |
| 2018-06-30 | AU$1.28 Million ≈ $906.75K |
AU$-1.84 Million ≈ $-1.30 Million |
-1.437x | +26.95% |
| 2017-06-30 | AU$1.44 Million ≈ $1.02 Million |
AU$-2.83 Million ≈ $-2.00 Million |
-1.968x | -100.34% |
| 2016-06-30 | AU$3.14 Million ≈ $2.22 Million |
AU$-3.08 Million ≈ $-2.18 Million |
-0.982x | -49.61% |
| 2015-06-30 | AU$4.14 Million ≈ $2.93 Million |
AU$-2.72 Million ≈ $-1.92 Million |
-0.656x | +69.35% |
| 2014-06-30 | AU$1.39 Million ≈ $983.02K |
AU$-2.98 Million ≈ $-2.11 Million |
-2.142x | -210.15% |
| 2013-06-30 | AU$4.48 Million ≈ $3.17 Million |
AU$-3.09 Million ≈ $-2.19 Million |
-0.691x | -149.63% |
| 2012-06-30 | AU$8.27 Million ≈ $5.85 Million |
AU$-2.29 Million ≈ $-1.62 Million |
-0.277x | +66.27% |
| 2011-06-30 | AU$2.40 Million ≈ $1.70 Million |
AU$-1.97 Million ≈ $-1.39 Million |
-0.820x | +24.19% |
| 2010-06-30 | AU$1.72 Million ≈ $1.22 Million |
AU$-1.86 Million ≈ $-1.31 Million |
-1.082x | +51.88% |
| 2009-06-30 | AU$841.51K ≈ $595.42K |
AU$-1.89 Million ≈ $-1.34 Million |
-2.249x | -155.50% |
| 2008-06-30 | AU$1.84 Million ≈ $1.30 Million |
AU$-1.62 Million ≈ $-1.15 Million |
-0.880x | +67.26% |
| 2007-06-30 | AU$1.36 Million ≈ $959.47K |
AU$-3.65 Million ≈ $-2.58 Million |
-2.688x | -576.13% |
| 2006-06-30 | AU$4.50 Million ≈ $3.18 Million |
AU$-1.79 Million ≈ $-1.26 Million |
-0.398x | +47.04% |
| 2005-06-30 | AU$2.28 Million ≈ $1.61 Million |
AU$-1.71 Million ≈ $-1.21 Million |
-0.751x | +14.84% |
| 2004-06-30 | AU$2.96 Million ≈ $2.09 Million |
AU$-2.61 Million ≈ $-1.84 Million |
-0.882x | -344.86% |
| 2002-06-30 | AU$8.49 Million ≈ $6.01 Million |
AU$-1.68 Million ≈ $-1.19 Million |
-0.198x | -52.42% |
| 2001-06-30 | AU$10.08 Million ≈ $7.13 Million |
AU$-1.31 Million ≈ $-927.34K |
-0.130x | -- |
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.